Last reviewed · How we verify
Lapatinib and ixempra
At a glance
| Generic name | Lapatinib and ixempra |
|---|---|
| Also known as | Lapatinib, Ixempra |
| Sponsor | Hung-Hsueh Chou |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma (PHASE2)
- Phase I Study of Ixabepilone Plus Lapatinib With or Without Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer (PHASE1)
- Lapatinib and Ixabepilone in Treating Patients With Advanced Solid Tumors (PHASE1)
- A Phase I Study of Lapatinib (Tykerb) Plus Ixabepilone (Ixempra) as 2nd-line Treatment for Patients With HER-2 Overexpressed Recurrent or Persistent Endometrial Carcinoma or Carcinosarcoma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lapatinib and ixempra CI brief — competitive landscape report
- Lapatinib and ixempra updates RSS · CI watch RSS
- Hung-Hsueh Chou portfolio CI